-
EP2655309
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2655309
| EP2655309 - METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.05.2016 Database last updated on 11.04.2026 | Most recent event Tooltip | 20.05.2016 | Application deemed to be withdrawn | published on 22.06.2016 [2016/25] | Applicant(s) | For all designated states Golden Biotechnology Corporation 101 Hudson Street Suite 2100 Jersey City NJ 07302 / US | [2013/44] | Inventor(s) | 01 /
LIU, Sheng-yung 15f, No 27-6 Sec 2 Jhong-jheng E. Rd. Danshuei New Taipei City / TW | 02 /
HWANG, San-bao 15f, No 27-6 Sec 2 Jhong-jheng E. Rd. Danshuel New Taipei City / TW | 03 /
WEN, Wu-che 15f, No 27-6 Sec 2 Jhong-jheng E. Rd. Danshuei New Taipei City / TW | [2013/44] | Representative(s) | Shah, Punita, et al HGF Limited 4th Floor, Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | [N/P] |
| Former [2014/07] | Shah, Punita, et al Harrison Goddard Foote LLP 4th Floor, Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | ||
| Former [2013/44] | Harrison Goddard Foote LLP 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | Application number, filing date | 11827110.5 | 15.04.2011 | WO2011US32785 | Priority number, date | US201113070308 | 23.03.2011 Original published format: US201113070308 | TW20209145853 | 24.12.2010 Original published format: TW 099145853 | TW20209131844 | 20.09.2010 Original published format: TW 099131844 | [2013/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012039793 | Date: | 29.03.2012 | Language: | EN | [2012/13] | Type: | A1 Application with search report | No.: | EP2655309 | Date: | 30.10.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.03.2012 takes the place of the publication of the European patent application. | [2013/44] | Search report(s) | International search report - published on: | KR | 29.03.2012 | (Supplementary) European search report - dispatched on: | EP | 04.08.2014 | Classification | IPC: | C07C49/517, C07C323/22, A61K31/122, A61K31/10, A61P35/00 | [2013/44] | CPC: |
C07H15/10 (EP,US);
A61K31/122 (KR);
A61P11/00 (EP);
A61P35/00 (EP,KR);
A61P43/00 (EP);
C07C323/22 (KR);
C07C403/02 (EP,US);
C07C403/08 (EP,US);
C07C403/10 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/44] | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON LUNGENKREBS | [2013/44] | English: | METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER | [2013/44] | French: | PROCÉDÉS ET COMPOSITIONS POUR TRAITER LE CANCER DU POUMON | [2013/44] | Entry into regional phase | 18.04.2013 | National basic fee paid | 18.04.2013 | Search fee paid | 18.04.2013 | Designation fee(s) paid | 18.04.2013 | Examination fee paid | Examination procedure | 18.04.2013 | Examination requested [2013/44] | 19.02.2015 | Amendment by applicant (claims and/or description) | 07.07.2015 | Despatch of a communication from the examining division (Time limit: M06) | 19.01.2016 | Application deemed to be withdrawn, date of legal effect [2016/25] | 15.02.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/25] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 07.07.2015 | Fees paid | Renewal fee | 18.04.2013 | Renewal fee patent year 03 | 13.10.2014 | Renewal fee patent year 04 | 10.04.2015 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.04.2014 | 04 M06 Fee paid on 13.10.2014 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] US7342137 (LIU SHENG-YUN et al.) [X] 15 * Antroquinonol, the preferred compound of the present application, for use in the treatment of cancer: see column 2, lines 29-65; column 3, lines 5-15; examples, and claims *[I] 1-14 | [Y] US2007116787 (YAO CHIH-JUNG et al.) [Y] 1-15 * Extracts of Antrodia camphorata for use in the treatment of cancer, including lung cancer: see paragraphs 5, 10, 6, and claims 1, 4 * | [XP] EP2233463 (GOLDEN BIOTECHNOLOGY CORP et al.) [XP] 1-11,13-15 * Compounds falling under the ones defined in claim 1 and their use for the treatment of lung cancer. See page 4,line 40; example 3, paragraph 29 and claims * | [XP] WO2009052711 (GOLDEN BIOTECHNOLOGY CORP et al.) * the whole document * | [X] HSIEH WAN-YU ET AL: "Abstract #3676: Antroquinonol inhibits tumorgenesis and metastasis in highly invasive non-small-cell lung cancer cells", 21 April 2009 (2009-04-21), XP002726800, Retrieved from the Internet | [XP] V. BHARATH KUMAR ET AL: "Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles", MUTATION RESEARCH/FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, vol. 707, no. 1-2, 24 December 2010 (2010-12-24), pages 42 - 52, XP055124441, ISSN: 0027-5107, DOI: 10.1016/j.mrfmmm.2010.12.009 [XP] 1-15 * Antroquinonol inhibits proliferation of Non Small Cell Lung Cancer (NSCLC) by inducing apoptosis in the cancer cells and is proposed for the treatment of lung cancer: see abstract, results and discussion and see conclusions in page 50 right hand column last paragraph and page 51 left hand column * DOI: http://dx.doi.org/10.1016/j.mrfmmm.2010.12.009 | [Y] WU HUNG ET AL: "Proteomic analysis of the effect of Antrodia camphorata extract on human lung cancer A549 cell.", PROTEOMICS FEB 2006, vol. 6, no. 3, February 2006 (2006-02-01), pages 826 - 835, XP002726069, ISSN: 1615-9853 [Y] 1-15 * The extracts of Antrodia camphorata effectively inhibit the proliferation of NSCLC cells by inducing apoptosis of cancer cells. Antrodia camphorata is defined as a "potent herbal medicine in cancer related cases": see abstract, discussion figures and see page 833 first paragraph of the section "discussion" * DOI: http://dx.doi.org/10.1002/pmic.200401341 | [Y] CHAN YU-YI ET AL: "Apoptotic effects of a high performance liquid chromatography (HPLC) fraction of Antrodia camphorata mycelia are mediated by down-regulation of the expressions of four tumor-related genes in human non-small cell lung carcinoma A549 cell.", JOURNAL OF ETHNOPHARMACOLOGY 17 FEB 2010, vol. 127, no. 3, 17 February 2010 (2010-02-17), pages 652 - 661, XP002726070, ISSN: 1872-7573 [Y] 1-15 * The extracts of Antrodia camphorata effectively inhibit the proliferation of NSCLC cells by inducing apoptosis of cancer cells: see abstract, discussion and figures * DOI: http://dx.doi.org/10.1016/j.jep.2009.12.008 | International search | [X] CN101225066 (GOLDEN BIOLOG TECHNOLOGY CO LT et al.) [X] | [X] GB2453808 (GOLDEN BIOTECHNOLOGY CORP et al.) [X] | [X] LEE, TZONG-HUEI ET AL.: "A New Cytotoxic Agent from Solid-State Fermented Mycelium of Antrodia camphorata", PLANTA MEDICA, vol. 73, no. 13, 2007, pages 1412 - 1415, XP002626076 [X] DOI: http://dx.doi.org/10.1055/s-2007-990232 | [X] YANG, SIEN-SING ET AL.: "New Constituents with iNOS Inhibitory Activity from Mycelium of Antrodia camphorata", PLANTA MEDICA, vol. 75, no. 5, 2009, pages 512 - 516, XP002626075 [X] DOI: http://dx.doi.org/10.1055/S-0029-1185305 |